MedPath
NMPA Approval

Cefprozil for Suspension

国药准字H20243605

April 24, 2024

Drug Information

头孢丙烯干混悬剂

口服混悬剂

1.875g(按C₁₈H₁₉N₃O₅S计)

化学药品

April 24, 2024

Company Information

Applicant Company

珠海市金海岸生物工业区

Manufacturing Company

珠海市金海岸生物工业区

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

头孢丙烯干混悬剂 - NMPA 批准文号 | MedPath